Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
BlackRock expands private equity focus with new financing initiative
BlackRock expands private equity focus with new financing initiative BlackRock, the world’s largest asset manager, is ramping up its presence in private equity by positioning itself as a key financier for alternative investment firms. The firm is looking to...
Oaktree raises $16bn for latest opportunities fund, deploys over $7bn
Oaktree raises $16bn for latest opportunities fund, deploys over $7bn Oaktree closed its Oaktree Opportunities Fund XII (Ops XII) at $16bn, making it one of the firm's largest funds to date.The fund has already committed or deployed more than $7bn across a diversified...
Sponsor Capital sells majority stake in Finnish HR firm StaffPoint to MB funds
Sponsor Capital sells majority stake in Finnish HR firm StaffPoint to MB funds Sponsor Capital exited its investment in StaffPoint, selling its 64% stake to MB Funds, which now holds a majority position in the Finnish HR service provider. The State Pension Fund of...